AP
BIVV

AHL Partners’s Bioverativ Inc. Common Stock BIVV Stock Holding History

AHL Partners’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$3.97M Sell
73,634
-18,350
-20% -$1M 0.06% 545
2017
Q3 		$5.25M Buy
91,984
+26,110
+40% +$1.53M 0.09% 389
2017
Q2 		$3.96M Buy
65,874
+49,542
+303% +$2.82M 0.08% 429
2017
Q1 		$890K Buy
+16,332
New +$804K 0.02% 808

Other funds holding BIVV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JIM
Jupiter Investment Management London, United Kingdom $6.26B AUM 13.19% 1-Year Est. Return

AHL Partners's BIVV Position: Q4 2017 in Review

AHL Partners reduced its Bioverativ Inc. Common Stock (BIVV) stake by 20% in Q4 2017, selling an estimated $1M and leaving 73,634 shares worth $3.97M. The position accounts for 0.06% of the portfolio, ranked #545.

AHL Partners first reported a position in BIVV in Q1 2017 and has held it in 4 quarters since. The position peaked at $5.25M in Q3 2017. 459 funds tracked by Wall St. Rank hold BIVV as of Q4 2017.

  • AHL Partners held 73,634 shares of Bioverativ Inc. Common Stock worth $3.97M as of Q4 2017.
  • AHL Partners sold 18,350 Bioverativ Inc. Common Stock shares in Q4 2017, an estimated $1M.
  • Bioverativ Inc. Common Stock made up 0.06% of AHL Partners's portfolio in Q4 2017, its #545 holding.
  • AHL Partners first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and has held it in 4 quarters since.
  • AHL Partners's Bioverativ Inc. Common Stock position peaked at $5.25M in Q3 2017.
  • 459 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q4 2017.

Based on AHL Partners's 13F filing for Q4 2017, filed 14 Feb 2018.